PhRMA and Community Oncology Alliance submitted comments to the FTC criticizing 340B contract pharmacies in response to the commission’s call for public input on PBMs’ business practices.
PhRMA and Private Oncology Practices Slam PBMs’ Role in 340B in Comments to FTC
Growth in 340B covered entities’ use of contract pharmacies to dispense 340B drugs, coupled with growth in pharmacy benefit managers’ control over these pharmacies, has given PBMs an outsized, profit-driven role in the 340B program that does not benefit patients, drug makers and independent oncology practices recently argued to the Federal Trade Commission.
Pharmaceutical Research and Manufacturers of America (PhRMA) and Community Oncology Alliance (COA) submitted comments to the FTC in response to the commission’s late February call for public input on PBMs’ business practices and their effect on drug affordability and access. Groups that represent 340B covered entities submitted comments too. FTC launched a formal investigation into PBM practices on June 7.
Drug makers and independent oncology practices slammed pharmacy benefit managers’ role in 340B contract pharmacy growth in recent public comment to the Federal Trade Commission.